Catch It While You Can: Smaller Firms Flock To China As Value Takes Center Stage
Quality Focus, Trade War To Spur Intra-Asian Deals?
Widely viewed as the largest fast-growing pharma market, China can nevertheless be hard to crack for small to mid-sized companies. But a new policy emphasis on quality and affordability are providing a rare opening for those with the right product mix and local partnerships in hand.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.